Your browser doesn't support javascript.
loading
High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors
Yao ZHAO; Xiaoyu DU; Yinkai DUAN; Xiaoyan PAN; Yifang SUN; Tian YOU; Lin HAN; Zhenming JIN; Weijuan SHANG; Jing YU; Hangtian GUO; Qianying LIU; Yan WU; Chao PENG; Jun WANG; Chenghao ZHU; Xiuna YANG; Kailin YANG; Ying LEI; Luke-W GUDDAT; Wenqing XU; Gengfu XIAO; Lei SUN; Leike ZHANG; Zihe RAO; Haitao YANG.
Protein & Cell ; (12): 877-888, 2021.
Article in En | WPRIM | ID: wpr-922482
Responsible library: WPRO
ABSTRACT
A new coronavirus (SARS-CoV-2) has been identified as the etiologic agent for the COVID-19 outbreak. Currently, effective treatment options remain very limited for this disease; therefore, there is an urgent need to identify new anti-COVID-19 agents. In this study, we screened over 6,000 compounds that included approved drugs, drug candidates in clinical trials, and pharmacologically active compounds to identify leads that target the SARS-CoV-2 papain-like protease (PLpro). Together with main protease (M
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
Search on Google
Full text: 1 Index: WPRIM Main subject: Antiviral Agents / Protease Inhibitors / Binding Sites / Recombinant Proteins / Mutagenesis, Site-Directed / Naphthoquinones / Protein Structure, Tertiary / Crystallography, X-Ray / Inhibitory Concentration 50 / Drug Evaluation, Preclinical Type of study: Diagnostic_studies / Screening_studies Limits: Humans Language: En Journal: Protein & Cell Year: 2021 Type: Article
Fulltext
Add to My VHL
Print
XML
Search on Google
Full text: 1 Index: WPRIM Main subject: Antiviral Agents / Protease Inhibitors / Binding Sites / Recombinant Proteins / Mutagenesis, Site-Directed / Naphthoquinones / Protein Structure, Tertiary / Crystallography, X-Ray / Inhibitory Concentration 50 / Drug Evaluation, Preclinical Type of study: Diagnostic_studies / Screening_studies Limits: Humans Language: En Journal: Protein & Cell Year: 2021 Type: Article